

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**ACOTEC**

**先瑞达**

**Acotec Scientific Holdings Limited**

**先瑞達醫療科技控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6669)**

**VOLUNTARY ANNOUNCEMENT  
APPROVAL FOR PERIPHERAL SCORING BALLOON DILATATION  
CATHETER E-PERIDGE® BY PRC NATIONAL MEDICAL  
PRODUCTS ADMINISTRATION**

This announcement is made by Acotec Scientific Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that on May 27, 2025, the Group received the registration approval from PRC National Medical Products Administration for the E-Peridge®, a Peripheral Scoring Balloon Dilatation Catheter. The E-Peridge® is used for pre-dilation of stenotic lesions in peripheral vessels, including the iliac artery, iliofemoral artery, femoral artery, popliteal artery, and renal artery. It provides effective and fixed anchoring points, aiding in the directed opening of lesions. While enlarging the vessel lumen, it reduces the elastic recoil of plaques or proliferative intimal tissue, thereby minimizing the occurrence of flow-limiting dissections and excessive vascular injury. This product can facilitate better vessel preparation for drug-coated balloon treatment. The Company will carry out marketing activities in PRC market when appropriate.

**THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET PERIPHERAL SCORING BALLOON DILATATION CATHETER E-PERIDGE® SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.**

By Order of the Board

**Acotec Scientific Holdings Limited**

**Jing LI**

*Chairperson of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, May 29, 2025

*As at the date of this announcement, the executive Director is Ms. Jing LI, the non-executive Directors are Mr. Silvio Rudolf SCHAFFNER, Mr. Arthur Crosswell BUTCHER and Ms. June CHANG, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.*